Recent drug approvals have increased the availability of biologic therapies for inflammatory bowel disease, making it difficult for patients with ulcerative colitis and Crohn’s disease to navigate treatment options.
Dr Brennan Spiegel and colleagues of California, USA developed a conjoint analysis to examine patient decision-making surrounding biologic medicines for inflammatory bowel disease.
The research team used the results to create an online patient decision aid that generates a unique “preferences report” for each patient to assist with shared decision-making with their provider.
The doctors administered an adaptive choice-based conjoint survey to inflammatory bowel disease patients that quantifies the relative importance of biologic attributes in decision making.
|Crohn’s disease patients were more likely to report side effect profile as most important|
|American Journal of Gastroenterology|
The conjoint software determined individual patient preferences by calculating part-worth utilities for each attribute.
The team conducted regression analyses to determine if demographic and disease characteristics predicted how patients made decisions.
640 patients completed the survey.
The researchers found that demographics and inflammatory bowel disease characteristics did not predict individual patient preferences; the main exception was inflammatory bowel disease type.
When compared to ulcerative colitis, Crohn’s disease patients were more likely to report side effect profile as most important.
Conversely, those with ulcerative colitis were more likely to value therapeutic efficacy.
Dr Spiegel's team concludes, "Biologic decision-making is highly personalized; demographic and disease characteristics poorly predict individual preferences, indicating that inflammatory bowel disease patients are unique and difficult to statistically categorize."
"The online decision tool resulting from this study may be used by patients to support shared decision-making and optimize personalized biologic selection with their provider."